Clinical effect of nicorandil combined with trimetazidine on multivessel coronary artery disease with unstable angina pectoris
Zhang Jingmei
Dai Wenli
Wang Su
Wu Xiangyu
Li Zhizhong
Abstract：Objective To analyze the therapeutic effect of nicorandil combined with trimetazidine on multivessel coronary artery disease with unstable angina pectoris.Methods Totally 98 patients with multivessel coronary artery disease and unstable angina pectoris were enrolled from January 2015 to January 2017 in Beijing Anzhen Hospital,Capital Medical University;they were randomly divided into observation group and control group,with 49 cases in each group.The control group had conventional drug treatment;the observation group took nicorandil 5 mg/time,3 times/d and trimetazidine 20 mg/time,3 times/d based on control group;both groups were treated for 6 months.N-terminal pro-brain natriuretic peptide (NT-proBNP),cardiac troponin Ⅰ (cTNⅠ),high-sensitivity C-reactive protein(hs-CRP) and left ventricular ejection fraction (LVEF) were tested before and after treatment;daily frequency,duration of angina pectoris and dose of nitroglycerin were recorded;incidences of cardio-cerebrovascular events and adverse reactions were analyzed.Results Mter 6 months of treatment,levels of NT-proBNP,cTnI and hs-CRP significantly decreased and LVEF significantly increased compared to those before treatment in both groups (P ＜ 0.05);levels of NT-proBNP,cTnI and hs-CRP in observation group were significantly lower and LVEF was significantly higher than those in control group [(826 ± 14) μg/L vs (973 ± 19) μg/L,(0.031 ±0.004) μg/L vs (0.044 ±0.006) μg/L,(0.58 ±0.11)mg/L vs (1.12 ±0.25)mg/L,(55 ±6)％ vs (50 ± 6) ％] (P ＜ 0.05).After treatment,daily frequency and duration of angina pectoris and dose of nitroglycerin significantly decreased (shortened) compared to those before treatment in both groups(P ＜ 0.05);daily frequency,duration of angina pectoris and dose of nitroglycerin in observation group were significantly less (shorter) than those in control group[(0.8 ± 0.4) times/d vs (1.3 ± 0.4) times/d,(2.3 ± 1.1) min/time vs (6.3 ± 1.7) min/time,(0.20 ± 0.12) pills/d vs (0.50 ± 0.31) pills/d] (P ＜ 0.05).Incidences of cardio-cerebrovascular events and adverse reactions in observation group were significantly lower than those in control group [4.1％ (2/49) vs 10.2％ (5/49),6.1％ (3/49) vs 10.2％ (5/49)] (P ＜ 0.05).Conclusion Nicorandil combined with trimetazidine has a satisfactory therapeutic effect on multivessel coronary disease with unstable angina pectoris,which can significantly relieve clinical symptoms and improve heart function.
Keywords：Angina,unstableMultivessel coronary diseaseTrimetazidineNicorandil
Publication Date：2017-09-30
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 1286-1289 )